SLN
NASDAQ
$10.49
Silence Therapeutics Plc (SLN)
Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $29.17 (+178.07%)
Market Cap
$494M
Free Cash Flow Yield
-13.29%
Beta (5Y)
0.91
Price Chart
Valuation
Market Cap$494M
P/S588.32
P/B9.32
Profitability
Total Revenue (TTM)$839K
Gross Profit (TTM)$667K
EBITDA-$78M
Operating Margin-3565%
EPS-$1.59
Financial Health
Free Cash Flow Yield-13.29%
Growth & Risk
Beta (5Y)0.91
Sharpe Ratio1.00